OR eager to sell shares of underperforming businessesNEW YORK (AP) — A number of President-elect Donald Trump 's most prominent Cabinet picks and appointees have been targeted by bomb threats and “swatting attacks," Trump's transition team said Wednesday. The FBI said it was investigating. “Last night and this morning, several of President Trump’s Cabinet nominees and Administration appointees were targeted in violent, unAmerican threats to their lives and those who live with them," Trump transition spokesperson Karoline Leavitt said in a statement. The attacks ranged from bomb threats to swatting, in which attackers initiate an emergency law enforcement response against a target victim under false pretenses, she said. The tactic has become a popular one in recent years. Leavitt said law enforcement and other authorities acted quickly to ensure the safety of those who were targeted and Trump and his transition team are grateful. Among those targeted were New York Rep. Elise Stefanik, Trump’s pick to serve as the next ambassador to the United Nations ; Matt Gaetz, Trump’s initial pick to serve as attorney general ; Oregon Rep. Lori Chavez-DeRemer, whom Trump chose to lead the Department of Labor , and former New York congressman Lee Zeldin, who has been tapped to lead the Environmental Protection Agency. Law enforcement officials are also looking into whether Susie Wiles, Trump’s incoming chief of staff, and Pam Bondi, the former Florida attorney general whom Trump has chosen as Gaetz’s replacement, and other incoming administration officials were also victims — as well as how each was targeted, according to a law enforcement official who spoke on condition of anonymity as the investigation continues. Wiles and Bondi did not immediately respond to requests for comment. The FBI said in a statement that it was “aware of numerous bomb threats and swatting incidents targeting incoming administration nominees and appointees" and was investigating with its law enforcement partners. White House spokesperson Saloni Sharma said President Joe Biden had been briefed and the White House is in touch with federal law enforcement and Trump's transition team. Biden “continues to monitor the situation closely," Sharma said, adding the president and his administration “condemn threats of political violence.” Stefanik's office said that, on Wednesday morning, she, her husband, and their 3-year-old son were driving home from Washington for Thanksgiving when they were informed of a bomb threat to their residence in Saratoga County. Police swept Stefanik’s home on Wednesday morning in response to the bomb threat but did not locate any explosive devices, New York State Police said. Zeldin said in a social media post that he and his family had also been threatened. “A pipe bomb threat targeting me and my family at our home today was sent in with a pro-Palestinian themed message,” he wrote on X . “My family and I were not home at the time and are safe." In Florida, the Okaloosa County sheriff’s office said on Facebook that it “received notification of a bomb threat referencing former Congressman Matt Gaetz’s supposed mailbox at a home in the Niceville area" Wednesday. While a family member resides at the address, the office said, Gaetz “is NOT a resident.” No threatening devices were found. Gaetz was Trump’s initial pick to serve as attorney general, but he withdrew from consideration after allegations that he paid women for sex and slept with underage women. Gaetz has vehemently denied any wrongdoing, and a Justice Department investigation into sex trafficking allegations ended with no charges against him. The threats follow a political campaign marked by disturbing and unprecedented violence. In July, a gunman opened fire at a Trump rally in Butler, Pennsylvania, grazing the then-candidate in the ear with a bullet and killing one of his supporters. The Secret Service later thwarted a subsequent assassination attempt at Trump's West Palm Beach, Florida, golf course when an agent spotted the barrel of a gun poking through a perimeter fence while Trump was golfing. Trump was also the subject of an Iranian murder-for-hire plot , with a man saying he had been tasked with planning the assassination of the Republican president-elect. Also this week, authorities arrested a man they say posted videos on social media threatening to kill Trump, according to court documents. In one video posted on Nov. 13, Manuel Tamayo-Torres threatened to shoot the former president while holding what appeared to be an AR-15 style rifle, authorities said Among the other videos he posted was one from an arena in Glendale, Arizona on Aug. 23, the same day Trump held a campaign rally there, according to court papers. An attorney for Tamayo-Torres did not immediately respond to a request for comment Wednesday. Public figures across the political spectrum have been targeted in recent years by hoax bomb threats and false reports of shootings at their homes. About a year ago the FBI responded to an uptick in such incidents at the homes of public officials, state capitols and courthouses across the country around the holidays. Many were locked down and evacuated in early January after receiving bomb threats. No explosives were found and no one was hurt. Some of those targeted last year were Georgia Lt. Gov. Burt Jones, Boston Mayor Michelle Wu and Ohio Attorney General Dave Yost. The judges overseeing the civil fraud case against Trump in New York and the criminal election interference case against him in Washington were both targeted earlier this year. Justice Department special counsel Jack Smith, who recently abandoned the two criminal cases he brought against Trump, was also the subject of a fake emergency call on Christmas Day last year. Earlier this year, schools, government buildings and the homes of city officials in Springfield, Ohio, received a string of hoax bomb threats after Trump falsely accused members of Springfield’s Haitian community of abducting and eating cats and dogs. And in 2022, a slew of historically Black colleges and universities nationwide were targeted with dozens of bomb threats, with the vast majority arriving during the celebration of Black History Month. The U.S. Capitol Police said in a statement Wednesday that anytime a member of Congress is the victim of a swatting' incident, “we work closely with our local and federal law enforcement partners.” The force declined to provide further details, in part to “minimize the risk of copy-cats.” Republican House Speaker Mike Johnson called the threats “dangerous and unhinged.” “This year, there was not just one but TWO assassination attempts on President Trump," he wrote on X . “Now some of his Cabinet nominees and their families are facing bomb threats.” He added: “It is not who we are in America.” ___ Richer reported from Washington. Associated Press writers Colleen Long and Eric Tucker in Washington, Scott Bauer in Madison, Wisconsin, and Anthony Izaguirre in Albany, New York, contributed to this report.Non-Fungible Token (NFT) Market to Grow by USD 68.16 Billion (2024-2028), Driven by Digital Art Demand and AI-Powered Market Evolution - Technavio

New York Giants rookie wide receiver Malik Nabers, who has been dealing with a toe injury, is active for Sunday's home game against the Indianapolis Colts in East Rutherford, N.J. Nabers was listed as questionable after missing practice on Thursday and being a limited participant on Friday. He had called himself a game-day decision on Thursday. Nabers, 21, has been one of the few bright spots for the Giants and leads the team with 97 receptions for 969 yards and four touchdown catches in 13 games (12 starts). The Giants (2-13) long have been out of playoff contention, while the Colts (7-8) are fighting to stay alive. "It's tough on everybody. It's not just tough on me. It's tough on everybody," Nabers said of the team's troubles. "I'm continuing to keep my mental (attitude) strong, continue to move forward, continue to try to better the team, better myself. Lead by example. I feel like that's really all we can do in this state of mind that we're going through." Selected sixth overall out of LSU, Nabers has caught 10 or more passes on three occasions but has just one touchdown catch over the past 10 games. Nabers needs three receptions to join former Giants Steve Smith (107 catches in 2009) and Odell Beckham Jr. (101 in 2016) as the only players in franchise history to haul in 100 receptions in a single season. The Giants inactives are defensive lineman Cory Durden, inside linebacker Micah McFadden, center John Michael Schmitz, cornerbacks Greg Stroman and Dee Williams, and emergency third quarterback Tim Boyle. The Colts inactives include quarterback Anthony Richardson, who already was ruled out. The others are defensive tackle Adetomiwa Adebawore, defensive end Isaiah Land, tight end Will Mallory and guard Dalton Tucker. --Field Level MediaANN ARBOR, Mich. (AP) — Michigan's defense of the national championship has fallen woefully short. The Wolverines started the season ranked No. 9 in the AP Top 25 , making them the third college football team since 1991 to be ranked worse than seventh in the preseason poll after winning a national title. Javascript is required for you to be able to read premium content. Please enable it in your browser settings.

NEW YORK , Dec. 10, 2024 /PRNewswire/ -- Report with market evolution powered by AI - The global alzheimer's disease therapeutics market size is estimated to grow by USD 5.41 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of 10.03% during the forecast period. Availability, research, and development of novel biomarkers is driving market growth, with a trend towards emergence of regenerative therapies. However, high cost of therapeutics development poses a challenge. Key market players include AB Science SA, AbbVie Inc., AgeneBio Inc., Biogen Inc., Cipla Ltd., Curasia Medilab, Denali Therapeutics Inc., Eisai Co. Ltd., Eli Lilly and Co., Grifols SA, H Lundbeck AS, Johnson and Johnson, Lifecare Neuro Products Ltd., Lupin Ltd., Novartis AG, Pfizer Inc., Psycogen Captab, Solco Healthcare, Teva Pharmaceutical Industries Ltd., and Aurobindo Pharma Ltd.. AI-Powered Market Evolution Insights. Our comprehensive market report ready with the latest trends, growth opportunities, and strategic analysis- View Free Sample Report PDF Key Market Trends Fueling Growth Alzheimer's disease, a leading cause of dementia among older adults, continues to be a major health concern. According to NCBI, over 6 million Americans are diagnosed with Alzheimer's and related dementias, leading to significant disability and increased deaths. The Alzheimer's disease therapeutics market is witnessing advancements in treatment with the introduction of drug classes like cholinesterase inhibitors (Aricept, Exelon, Razadyne) and Amyloid beta inhibitors (Crenezumab). Biological therapies, such as Tau antibody, are also in the pipeline. Cognitive assessment systems and smartphones aid in early diagnosis. Distribution channels, including hospitals, hospital pharmacies, online pharmacies, and e-commerce platforms, facilitate access to these drugs. Men and women, especially Medicare beneficiaries, are the primary consumers. Memantine, another drug class, targets memory impairment and thinking skills. Life expectancy and disability are significant factors driving market growth. Everyday tasks and social skills are also affected, making these therapies essential. Drug discovery techniques continue to evolve, increasing the prescription rate. Alzheimer's disease is a significant health concern for the elderly population, characterized by memory loss and cognitive decline. The disease is marked by the presence of amyloid B-peptide plaques and tau neurofibrillary tangles. Despite extensive research, no disease-modifying treatments have been discovered. Neuronal death, synaptic failure, dendritic and axonal atrophy are some of the disease's progressive symptoms. Researchers continue their efforts to find curative therapies, focusing on understanding the underlying mechanisms of neuronal damage and cognitive impairment. The Alzheimer's disease therapeutics market is currently in search of effective treatments to address this unmet medical need. Insights on how AI is driving innovation, efficiency, and market growth- Request Sample! • Alzheimer's disease, a leading cause of dementia, affects over 6 million Americans, with numbers projected to triple by 2050. The Alzheimer's disease therapeutics market faces challenges in advancing treatment, with current options including cholinesterase inhibitors like Aricept and Exelon, and NMDA receptor antagonist Memantine. Amyloid beta inhibitors, such as Crenezumab, are in the pipeline. Behavioral skills and thinking impairments impact everyday tasks, leading to disability and increased healthcare costs for diagnosed patients. Biological therapies, like Tau antibody, show promise. Distribution channels, including hospitals, hospital pharmacies, e-commerce platforms, and online pharmacies, aim to improve access. Drug discovery techniques and cognitive assessment systems aid diagnosis among Medicare beneficiaries, mostly women. Life expectancy and memory impairment drive high prescription rates. Smartphones and the Internet facilitate access to e-commerce services, enabling easier access to these essential medications. • The Alzheimer's disease therapeutics market is significant due to the growing number of patients requiring symptomatic relief. Currently, available treatments only manage the symptoms of the disease. The pressing need for disease-modifying therapeutics arises from the increasing prevalence of Alzheimer's disease. Researchers are actively working on developing such treatments, but the high development costs and challenges in clinical trials pose obstacles to market expansion. The estimated cost of an Alzheimer's disease therapeutics development program is approximately USD5.6 billion , and the process takes around 13 years, from preclinical studies to US FDA approval. Insights into how AI is reshaping industries and driving growth- Download a Sample Report This alzheimer's disease therapeutics market report extensively covers market segmentation by 1.1 Hospital pharmacy 1.2 Retail pharmacy 1.3 E-commerce pharmacy 2.1 Cholinesterase inhibitors 2.2 N-methyl-D-aspartate receptor antagonist 2.3 Others 3.1 North America 3.2 Europe 3.3 Asia 3.4 Rest of World (ROW) 1.1 Hospital pharmacy- The hospital pharmacy segment of the Alzheimer's disease therapeutics market is experiencing significant growth due to the large-scale demand for these drugs in hospitals. This trend is driven by several factors, including increasing government investments in healthcare infrastructure in countries like India and China , the expansion of hospital facilities in developing nations, and the rising number of Alzheimer's disease cases worldwide. As a result, hospitals are becoming major distribution channels for Alzheimer's disease therapeutics. These factors collectively are expected to boost the growth of the hospital segment of the Alzheimer's disease therapeutics market during the forecast period. Download complimentary Sample Report to gain insights into AI's impact on market dynamics, emerging trends, and future opportunities- including forecast (2024-2028) and historic data (2018 - 2022) The Alzheimer's disease therapeutics market encompasses innovative treatments for neurodegenerative diseases, primarily Alzheimer's and dementias. Two major categories include Amyloid beta inhibitors and biological therapies. These treatments aim to slow down the progression of these conditions by targeting the buildup of beta-amyloid plaques and tau tangles in the brain. Both men and women are affected, with women making up two-thirds of the estimated 5.8 million Americans living with Alzheimer's disease. Life expectancy plays a significant role, as the majority of Medicare beneficiaries, who are aged 65 and above, are at increased risk. The prescription rate for these therapies is growing as more clinics and hospitals integrate cognitive assessment systems into their routine patient care. Memory impairment, thinking, behavioral skills, and social skills are common symptoms, affecting everyday tasks and quality of life. Alzheimer's disease, a leading cause of dementia and neurodegenerative diseases, affects memory impairment, thinking, and social skills in older adults. The Alzheimer's disease therapeutics market is witnessing significant advancements in treatment with the development of various drug classes, including cholinesterase inhibitors (Aricept, Exelon, Razadyne) and Amyloid beta inhibitors (Crenezumab). Biological therapies, such as Tau antibody, are also under investigation. Cognitive assessment systems aid in diagnosis, while distribution channels, including hospitals, hospital pharmacies, online pharmacies, and e-commerce platforms, facilitate access to these essential medications. With an increasing number of diagnosed patients, particularly among older adults, life expectancy, and Medicare beneficiaries, the prescription rate for Alzheimer's disease therapeutics continues to rise. The use of drug discovery techniques and technological advancements, such as smartphones and the Internet, are revolutionizing the way these therapies are administered and monitored. Despite these advancements, Alzheimer's disease remains a significant cause of disability and deaths, with a disproportionate impact on Men and Women. The pipeline drugs offer hope for future treatments, aiming to slow down the progression of the disease and improve the quality of life for those affected. 1 Executive Summary 2 Market Landscape 3 Market Sizing 4 Historic Market Size 5 Five Forces Analysis 6 Market Segmentation Distribution Channel Hospital Pharmacy Retail Pharmacy E-commerce Pharmacy Drug Class Cholinesterase Inhibitors N-methyl-D-aspartate Receptor Antagonist Others Geography North America Europe Asia Rest Of World (ROW) 7 Customer Landscape 8 Geographic Landscape 9 Drivers, Challenges, and Trends 10 Company Landscape 11 Company Analysis 12 Appendix Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Technavio Research Jesse Maida Media & Marketing Executive US: +1 844 364 1100 UK: +44 203 893 3200 Email: [email protected] Website: www.technavio.com/ SOURCE TechnavioOver half of Canadian businesses regret recent software purchase